Akebia Therapeutics Inc

자세한 내용은 Akebia Therapeutics Inc 회사

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

회사 정보

종목 코드 AKBA

회사 이름Akebia Therapeutics Inc

상장일Mar 20, 2014

CEOMr. John P. Butler

직원 수181

유형Ordinary Share

회계 연도 종료Mar 20

주소245 First Street

도시CAMBRIDGE

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호02142

전화16178712098

웹사이트https://akebia.com/

종목 코드 AKBA

상장일Mar 20, 2014

CEOMr. John P. Butler

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Ms. Leanne M. Zumwalt

Independent Director

79.40K

+81.69%

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

--

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

--

이름

이름/직위

직위

주식 보유

변동

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Thu, Jul 31

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

5.32%

The Vanguard Group, Inc.

4.83%

State Street Global Advisors (US)

2.59%

Alerce Investment Management, L.P.

2.19%

Satter Muneer A

2.19%

Other

82.88%

주주

비율

BlackRock Institutional Trust Company, N.A.

5.32%

The Vanguard Group, Inc.

4.83%

State Street Global Advisors (US)

2.59%

Alerce Investment Management, L.P.

2.19%

Satter Muneer A

2.19%

Other

82.88%

주주 유형

주주

비율

Investment Advisor

13.32%

Investment Advisor/Hedge Fund

10.58%

Hedge Fund

9.31%

Individual Investor

3.61%

Research Firm

2.48%

Private Equity

2.19%

Bank and Trust

0.14%

Pension Fund

0.04%

Insurance Company

0.03%

Other

58.30%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

281

109.59M

41.73%

+26.45M

2025Q1

280

111.54M

42.50%

+30.68M

2024Q4

258

78.54M

36.08%

+7.41M

2024Q3

257

64.16M

30.51%

-2.18M

2024Q2

248

61.31M

29.27%

-7.52M

2024Q1

290

61.37M

29.36%

-12.30M

2023Q4

289

58.79M

31.24%

-20.79M

2023Q3

300

57.28M

30.45%

-25.18M

2023Q2

308

56.18M

30.22%

-26.52M

2023Q1

315

56.14M

30.23%

-26.40M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

13.97M

5.32%

+133.23K

+0.96%

Mar 31, 2025

The Vanguard Group, Inc.

12.69M

4.83%

+1.80M

+16.55%

Mar 31, 2025

State Street Global Advisors (US)

6.81M

2.59%

+501.11K

+7.95%

Mar 31, 2025

Alerce Investment Management, L.P.

5.75M

2.19%

--

Dec 31, 2024

Satter Muneer A

5.75M

2.19%

+5.75M

--

Dec 31, 2024

Geode Capital Management, L.L.C.

5.03M

1.92%

+235.65K

+4.91%

Mar 31, 2025

Great Point Partners, LLC

4.97M

1.89%

+4.97M

--

Mar 31, 2025

Renaissance Technologies LLC

4.01M

1.53%

+182.30K

+4.77%

Mar 31, 2025

Citadel Advisors LLC

3.65M

1.39%

+2.26M

+163.86%

Mar 31, 2025

Franklin Advisers, Inc.

2.67M

1.02%

+2.50M

+1495.36%

Mar 31, 2025

3.715USD

Akebia Therapeutics Inc

3.715

개요

회사

금융